Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension by unknown
RESEARCH ARTICLE Open Access
Efficacy of 1, 5, and 20 mg oral sildenafil in
the treatment of adults with pulmonary
arterial hypertension: a randomized,
double-blind study with open-label
extension
Carmine Dario Vizza1* , B. K. S. Sastry2, Zeenat Safdar3, Lutz Harnisch4, Xiang Gao5, Min Zhang6,
Manisha Lamba5 and Zhi-Cheng Jing7
Abstract
Background: In a previous study, 6-minute walk distance (6MWD) improvement with sildenafil was not dose dependent
at the 3 doses tested (20, 40, and 80 mg 3 times daily [TID]). This study assessed whether lower doses were less effective
than the approved 20-mg TID dosage.
Methods: Treatment-naive patients with pulmonary arterial hypertension were randomized to 12 weeks of double-blind
sildenafil 1, 5, or 20 mg TID; 12 weeks of open-label sildenafil 20 mg TID followed. Changes from baseline in 6-minute
walk distance (6MWD) for sildenafil 1 or 5 mg versus 20 mg TID were compared using a Williams test. Hemodynamics,
functional class, and biomarkers were assessed.
Results: The study was prematurely terminated for non-safety reasons, with 129 of 219 planned patients treated. At week
12, 6MWD change from baseline was significantly greater for sildenafil 20 versus 1 mg (P = 0.011) but not versus 5 mg. At
week 24, 6MWD increases from baseline were larger in those initially randomized to 20 versus 5 or 1 mg (74 vs 50 and
47 m, respectively). At week 12, changes in hemodynamic parameters were generally small and variable between
treatment groups; odds ratios for improvement in functional class were not statistically significantly different.
Improvements in B-type natriuretic peptide levels were significantly greater with sildenafil 20 versus 1 but not 5 mg.
Conclusions: Sildenafil 20 mg TID appeared to be more effective than 1 mg TID for improving 6MWD; sildenafil 5 mg
TID appeared to have similar clinical and hemodynamic effects as 20 mg TID.
Trial registration: ClinicalTrials.gov NCT00430716 (Registration date: January 31, 2007).
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Background
Pulmonary arterial hypertension (PAH) is a fatal disease in
which increasing pulmonary vascular resistance ultimately
culminates in right ventricular failure and death [1, 2].
The phosphodiesterase type 5 (PDE5) inhibitor sildenafil
is approved to treat adult patients with PAH [2]; pediatric
use is approved in the European Union.
In the 12-week, randomized, double-blind, SUPER-1
study [3], statistically significant improvements in 6-minute
walk distance (6MWD) were observed with sildenafil versus
placebo in treatment-naive patients at all 3 tested doses
(20, 40, and 80 mg 3 times daily [TID]); improvements
were similar among groups and did not appear to be dose
related. However, hemodynamic parameters, including
mean pulmonary arterial pressure (mPAP), cardiac index,
and pulmonary vascular resistance index (PVRI), appeared
to improve dose dependently with sildenafil treatment.
Sildenafil 20 mg TID appeared to reach the plateau of the
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dose-response curve for 6MWD [3] and was confirmed by
subsequent population pharmacokinetic and pharmacody-
namic analysis [4].
This study was conducted to fulfill a postapproval com-
mitment from the US Food and Drug Administration
(FDA) to further explore the sildenafil dose-response
curve. This multinational, randomized, double-blind study
investigated whether low doses of sildenafil (1 and 5 mg
TID) were less effective in adult patients with PAH than
the currently approved 20-mg TID dose.
However, before completion of this low-dose study,
results from another randomized, double-blind, placebo-
controlled study (PACES-1) became available that sup-
ported approval of a clinical worsening indication by the
FDA [5]. PACES-1 evaluated oral sildenafil in patients with
PAH who were receiving stable epoprostenol therapy [6].
In PACES-1, ≥75% of patients were titrated from sildenafil
20 mg TID, received during the first 4 weeks, to sildenafil
40 mg TID at week 4, and then to sildenafil 80 mg TID at
week 8 (and were maintained on this dose, as patients toler-
ated). After 16 weeks, 6MWD, hemodynamic parameters,
and functional class improved. There was a significant delay
in time to clinical worsening (TTCW) [6], defined as death,
lung transplantation, hospitalization due to PAH, initiation
of bosentan therapy, or clinical deterioration requiring
a change in epoprostenol therapy, with sildenafil com-
pared with placebo. The effect was apparent by week 4,
when all patients were receiving sildenafil 20 mg TID
(P = 0.0074) [4].
Following approval of the clinical worsening indication
in the United States in 2009, the FDA released Pfizer from
the postapproval commitment to conduct a low-dose
study. The study was subsequently terminated (June 2010)
based on the recommendation of the data monitoring
committee (DMC) because sildenafil 20 mg TID had been
shown to reduce time to clinical worsening in PACES-1
and also acknowledging that with recruitment issues the
study was unlikely to meet original enrollment targets.
Accumulated results are presented here.
Methods
Study design
Patients were stratified by baseline 6MWD (<325 or
≥325 m) and PAH etiology and randomly assigned 1:1:1
to receive 12 weeks of treatment with sildenafil 1, 5, or
20 mg TID, respectively, during the double-blind phase
of the study (Fig. 1). Patients who completed the double-
blind phase were eligible for a 12-week, open-label
extension in which they received sildenafil 20 mg TID.
Patients who withdrew during the study were to be
followed up for safety assessments 30 days after the last
treatment date.
The primary objective of the study was to demonstrate
a dose response for 6MWD for 1, 5, and 20 mg TID oral
sildenafil. The hypothesis was that there is a dose that is
significantly less effective than sildenafil 20 mg TID.
Secondary objectives included assessment of the safety
and tolerability of low-dose sildenafil during the 12 weeks
of treatment in patients with PAH and evaluation of the
effects of sildenafil on perceived PAH-progression bio-
markers (B-type natriuretic peptide [BNP]/pro-BNP
levels and tricuspid annular plane systolic excursion
[TAPSE]). The study protocol and amendments were
reviewed and approved by the Institutional Review
Board and/or Independent Ethics Committee at each
participating center (Additional file 1); informed consent
was obtained from all patients.
Patients
Patients were aged >18 years with idiopathic or heritable
PAH or PAH associated with connective tissue disease
or surgical repair (≥5 years before enrollment) of atrial
septal defect, ventricular septal defect, patent ductus
arteriosus, or aorto-pulmonary window and 6MWD 100
to 450 m. PAH, defined as mPAP ≥25 mmHg and pul-
monary artery wedge pressure ≤15 mmHg at rest (or a
left ventricular end diastolic pressure <14 mmHg and
absence of mitral stenosis on echocardiography), was
confirmed by right heart catheterization (RHC) within
12 weeks before randomization. Patients had to be on
stable (≥30 days before RHC) doses of background
medication.
Patients were excluded for use of PAH-specific ther-
apy, including prostacyclin, PDE5 inhibitors, and
endothelin-receptor antagonists (ETRAs); nitrates or ni-
tric oxide donors; protease inhibitors, such as ritonavir
and saquinavir; ketoconazole, itraconazole, or other
strong cytochrome P450 (CYP) 3A4 inhibitors; and
alpha blockers. Patients previously receiving any of these
drugs must have stopped use for ≥1 month before
screening. Concomitant medications were to remain
stable throughout the treatment phase of the study;
patients withdrew if they required additional PAH-
specific therapy.
Assessments
Six-minute walk distance was assessed at baseline (day
1) and at weeks 4, 8, 12, 16, 20, and 24 as close to
sildenafil trough levels as possible (ie, just before dosing
and ≥4 h after the last scheduled dose). Borg dyspnea
score was assessed at the end of the 6MWD evaluation.
Hemodynamic status was assessed at baseline and week
12, using RHC. World Health Organization functional
class was assessed at baseline; weeks 4, 8, 12, and 24;
and follow-up.
Time to clinical worsening was assessed during the
double-blind phase. Clinical worsening was defined as
death, lung transplantation, hospitalization attributable
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to pulmonary hypertension, or initiation of prostacyclin
or ETRA therapy.
Blood samples for determination of BNP/pro-BNP
levels were collected at baseline and at weeks 1, 4, 8, 12,
16, 20, and 24. Echocardiography for TAPSE was per-
formed at baseline and at weeks 4, 8, 12, and 24. A 2-
dimensional Doppler examination was performed using
an apical 4-chamber view. TAPSE index was measured
as the total displacement of the tricuspid annulus (cm)
from end diastole to end systole, with values represent-
ing the average TAPSE of 3 to 5 beats.
For pharmacokinetic analysis, blood samples were col-
lected at the baseline visit (between 15 min and 3 h, >3
and 6 h, and >6 and 8 h postdose), week 1 (immediately
after BNP/pro-BNP sampling), weeks 4 and 8 (immedi-
ately before 6MWD), and week 12 (between 15 min and
3 h and between >3 and 6 h postdose, immediately be-
fore 6MWD, between >6 and 8 h postdose, and during
RHC assessment).
Adverse events (AEs) were monitored throughout the
study. Laboratory testing and physical examinations were
performed at screening, baseline, and weeks 4, 8, and 12.
Dose selection
The relationship between 6MWD and sildenafil expos-
ure could not be modeled because 6MWD had reached
a plateau across all SUPER-1 dose groups [3]. Therefore,
the relationship between PVRI and exposure was used
to select doses predicting exposures from the population
pharmacokinetic/pharmacodynamic model. The average
sildenafil plasma concentration required to achieve 50%
effect (EC50) on PVRI was approximately 3 ng/mL; at a
20-ng/mL concentration, sildenafil appeared to have a
90% maximal effect (EC90) on PVRI [4]. Therefore, after
receipt of 20 mg TID, sildenafil concentrations were an-
ticipated to be > EC90 for the entire 8-hour dosing inter-
val; for 5 mg TID, above EC50 for the entire 8-hour
dosing interval but < EC90 for most of the interval; and
for 1 mg TID, sildenafil concentrations were anticipated
to be at approximately EC50.
Pharmacokinetic modeling
Population modeling characterized sildenafil pharmaco-
kinetics; available sildenafil concentrations from all
patients across all visits were merged to develop a non-
linear mixed effects model (NONMEM®, version 7.2;
ICON Development Solutions, Ellicott City, MD). Esti-
mation was performed for underlying pharmacokinetic
parameters affecting the concentration-time profile.
Only covariates that were previously reported to affect
pharmacokinetic parameters [5] were tested in the
model. To test for appropriateness, a visual predictive
check was performed by calculating the median and 90%
prediction interval from 500 simulations of the resulting
population pharmacokinetic model.
Statistical analysis
The estimated sample size was based on the primary end-
point and was determined using simulations. Assuming a
treatment effect of 30 m for sildenafil 20 versus 1 mg TID,
with a standard deviation of 60 m [3], 70 patients per
group were required to detect a difference between treat-
ments with 80% power at a 1-sided significance level of
2.5%. Allowing for 4% postrandomization nonevaluability,
approximately 219 patients (73 per group) were required
to be randomized.
For the primary endpoint, statistical significance was
assessed with a 1-sided Williams trend test on the
intent-to-treat (ITT) population; the ITT population
consisted of randomized patients who received ≥1 dose
of study medication. The highest noneffective dose (ie,
the highest dose that is statistically significantly different
from sildenafil 20 mg) was determined. Missing values
were replaced according to the last observation carried
forward (LOCF) in the primary analysis and via multiple
imputation for sensitivity analyses.
Time, wk
21 days
1 4 8 12 16 20 24
30 days
Screen
Sildenafil 1 mg TID
Sildenafil 5 mg TID






Double-Blind Phase (Dose Response) Open-Label Phase
Sildenafil 20 mg TID
Follow-up
Fig. 1 Study design. Legend: TID = 3 times daily
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Additionally, changes in the primary endpoint were
modeled by analysis of covariance (ANCOVA) with ran-
domized treatment, baseline 6MWD, and etiology as
stratification factors. Pairwise treatment group differ-
ences were estimated. In the open-label phase, changes
to week 24 (LOCF) were analyzed using this ANCOVA
model (but also including week 12 [LOCF] in the model)
if there was a nonmissing post–week-12 assessment.
Secondary endpoints (including hemodynamic parame-
ters) were assessed in the ITT population using LOCF; co-
variates for each analysis included baseline value as well as
the randomization strata of baseline 6MWD and etiology.
Methods for LOCF, time to clinical worsening (TTCW),
and Borg assessments are described in Additional file 2. For
secondary endpoints, statistical significance was assessed
based on nominal P values (<0.05; 2-sided) without adjust-
ment for multiplicity.
Results
The study was conducted at 34 centers in Europe, Asia,
Russia, the United States, and Brazil. Of the planned 219
patients, 169 were screened, 130 were randomized, and 129
were treated (1 patient [sildenafil 1 mg] did not meet entry
criteria). Treated patients were mostly female and mostly
Asian; baseline cardiac index was significantly higher in the
sildenafil 20-mg group versus the 1- and 5-mg groups
(P = 0.0328 and 0.0030, respectively; Table 1).
Patient disposition is shown in Fig. 2. Two patients
died during the double-blind phase (pneumonia [1 mg
TID; death was the reason for discontinuation] and
acute exacerbation of idiopathic pulmonary fibrosis
[5 mg TID; patient was enrolled in error and received
4 days of treatment]), neither of which was considered
to be treatment related; no deaths were reported in the
open-label phase (Fig. 2).
Sildenafil concentration
Overall, 129 patients provided 1068 sildenafil concentra-
tions. A 1-compartment pharmacokinetic model ad-
equately described the sparse data. From this model, the
estimated apparent clearance was 43.9 (95% CI, 39.3–
48.6) L/h, the apparent volume of distribution was 458
(95% CI, 393–523) L, and the absorption rate constant
was 2.16 (95% CI, 1.48–2.84) h−1. Coadministration of
weak or moderate CYP3A4 inhibitors (n = 12 patients/
110 samples) reduced CL/F by 40.4% (95% CI, 19.2%–
61.6%). The model supported dose proportionality of
exposures.
The limit of quantification of the pharmacokinetic assay
was 1 ng/mL; 134 samples were below the limit of quanti-
fication (BLQ). The majority of BLQ samples (approxi-
mately 75%) were measured at the 1-mg TID sildenafil
dose, but had little effect on the population pharmacoki-
netic parameter estimates.
Figure 3 represents the sildenafil concentration data.
Because a small accumulation existed between the first (at
baseline visit) and subsequent doses, only concentrations
after the second and subsequent doses are shown (for data
including baseline visit, see Additional file 3). Concentra-
tions after concomitant administration of CYP3A4 inhibi-
tors were adjusted for the estimated effect. Visual
inspection of observed concentration distribution across
each dose indicated consistency of the observed data with
the model. In particular, in the 8 h after drug administra-
tion, most of the determinations in the 1-mg TID group
had a concentration below 3 ng/mL, whereas in the 5-mg
TID and 20-mg TID groups, most of the determinations
had a concentration above 3 ng/mL, which is the average
sildenafil plasma concentration required to achieve 50%
effect (EC50) on PVRI [4]. An exploratory assessment (see
Additional files 4 and 5) of the relationship between
6MWD, PVR, and steady-state concentrations revealed a
significant relationship for 6MWD, whereas only a small
trend could be seen for PVR across the concentration
range observed (Additional files 6 and 7).
Six-minute walk distance
At week 12, compared with baseline, the increase in
6MWD was of a magnitude consistent with estimates of
clinical significance [7, 8] in 5- and 20-mg TID groups
and smaller although statistically significant in the 1-mg
TID group. Among dose groups, the mean change in
6MWD from baseline was statistically significantly differ-
ent only for the sildenafil 20- versus 1-mg group (Fig. 4a).
Analysis of change from baseline in 6MWD at week 12
showed a statistically significant (P = 0.011) difference be-
tween sildenafil 1 mg and 20 mg, but not sildenafil 5 mg
and 20 mg (Table 2). The results were confirmed by an
analysis of variance; the mean treatment difference
between sildenafil 20 mg and 1 mg was 23 (3–43) m and
between 20 mg and 5 mg was –3 (–23 to 17) m (P = 0.02
and 0.76, respectively).
Patients with baseline 6MWD <325 m at baseline had
greater increases in 6MWD after sildenafil treatment
than patients with baseline 6MWD ≥325 m (Fig. 4b).
Differences in 6MWD between Asian and non-Asian
patients were noted for sildenafil 1 mg but not for 5 mg
or 20 mg (Fig. 5a and b); the number of non-Asian
patients was small.
During the open-label period (weeks 12 to 24), in
which all patients received sildenafil 20 mg TID, patients
who received sildenafil 1 mg TID during the double-
blind phase (weeks 0 to 12) had a larger increase in
6MWD than patients who received sildenafil 5 mg TID
(mean change, 31 vs 6 m, respectively); the magnitude of
change was similar between patients who received
sildenafil 1 mg and 20 mg TID in the double-blind phase
(mean change, 31 vs 26 m; Fig. 4a).
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Secondary and tertiary evaluations
Hemodynamics
Compared with baseline, there was a trend toward re-
duction in pulmonary vascular resistance (PVR) at
week 12 in all groups; the mean reduction was statis-
tically significantly different from 0 only in the 20-mg
TID group (ie, 95% CIs do not include 0). There were
no statistically significant differences among treatment
groups for change in PVR (Table 3). Changes at week
12 in the additional hemodynamic parameters were
generally small and variable between groups.
Functional class and clinical worsening
Most patients in each treatment group remained in
the same functional class from baseline to week 12;
the same was true through week 24 (Table 4). Odds
ratios (ORs) showed no significant differences for
functional class between sildenafil 20 mg and the 5-
mg (OR, 1.08 [95% CI, 0.35–3.32]; P = 0.897) or 1-mg
(OR, 1.55 [95% CI, 0.50–7.78]; P = 0.448) dose at
week 12. Similarly, there were no differences between
sildenafil 20 mg and the 5-mg (OR, 1.31 [95% CI,
0.42–4.05]; P = 0.639) or 1-mg (OR, 0.93 [95% CI,
0.30–2.91]; P = 0.899) dose at week 24. Four patients
(sildenafil 1 mg and 5 mg, n = 1 each; sildenafil
20 mg, n = 2) reported events defined as clinical wors-
ening (initiation of ETRA therapy [sildenafil 5-mg
patient] and hospitalization due to PAH [all others]).
Table 1 Baseline Patient Demographic and Clinical
Characteristics







Women, n (%) 28 (68) 33 (77) 26 (58)
Age, y 42.5 (16.5) 44.4 (17.4) 46.4 (17.7)
Range 18–77 18–78 20–88
Race, n (%)
White 11 (27) 11 (26) 14 (31)
Black 2 (5) 2 (5) 1 (2)
Asian 27 (66) 30 (70) 30 (67)
Other 1 (2) 0 0
Height, cm 159.0 (11.3) 160.2 (10.7) 160.7 (8.7)
Range 130.0–181.6 129.0–189.0 147.0–181.0
Weight, kg 61.7 (17.0) 63.1 (19.7) 61.4 (15.7)
Range 32.0–117.0 26.5–126.1 35.0–100.0
BMI, kg/m2 24.3 (5.6) 24.3 (6.6) 23.8 (6.2)
Range 15.6–35.8 13.3–42.1 15.6–38.6
WHO functional class, n (%)
I 0 1 (2.3) 3 (6.7)
II 25 (61.0) 22 (51.2) 27 (60.0)
III 16 (39.0) 16 (37.2) 13 (28.9)
IV 0 1 (2.3) 0
Missing 0 3 (7.0) 2 (4.4)
Etiology, n (%)
Idiopathic 30 (73) 31 (72) 34 (76)
Mean duration (range)
since diagnosis, y
1.1 (0–6.7) 0.7 (0–6.5) 0.9 (0–14.9)
Associated with CTD 6 (15) 8 (19) 5 (11)
Mean duration (range)
since diagnosis, y
0.6 (0–2.3) 0.4 (0–1.8) 0.4 (0–1.9)
Associated with
surgical repair
5 (12) 4 (9) 6 (13)
Mean duration (range)
since diagnosis, y
5.9 (0.3–14.2) 3.5 (0–7.3) 4.5 (0–15.7)
6MWD, ma 347.5 (67.3) 347.7 (73.4) 340.4 (76.3)
Range 167.5–441.5 109.0–455.0 114.0–429.0
Heart rate, bpmb 83.6 (17.2) 78.9 (16.4) 80.1 (15.0)
Range 48–122 42–113 53–110
RAP, mmHgc 10.5 (5.1) 10.1 (6.1) 8.4 (4.7)
Range 4.0–20.0 2.0–23.0 2.0–27.0
mPAP, mmHgc 57.2 (21.9) 55.4 (19.7) 51.1 (21.4)
Range 25.0–110.0 26.3–117.0 25.0–106.0
Cardiac index, L/min/m2d 2.1 (0.7) 2.3 (0.6) 2.8 (1.2)
Range 1.0–3.5 1.0–3.8 1.1–5.9
PVR, Wood unitse 15.7 (9.9) 13.2 (8.3) 11.7 (9.1)
Range 3–43 3–48 2–35
Table 1 Baseline Patient Demographic and Clinical
Characteristics (Continued)
MVO2, %
f 63.4 (10.5) 63.0 (9.6) 64.3 (14.5)
Range 41–82 42–77 31–90
TAPSE indexg 1.25 (0.62) 1.2 (0.71) 1.36 (0.83)
Range 0.1–2.6 0.1–2.5 0.2–2.8
Borg dyspnea scoreh 2.9 (2.5) 3.1 (1.9) 2.8 (2.1)
Range 0–10 0–8 0–9
All values are presented as mean (SD) unless stated otherwise
6MWD 6-minute walk distance, BMI body mass index, bpm beats per minute,
CTD connective tissue disease, mPAP mean pulmonary arterial pressure, MVO2
mixed venous oxygen saturation, PVR pulmonary vascular resistance, RAP right
atrial pressure, TAPSE tricuspid annular plane systolic excursion, TID 3 times
daily, WHO World Health Organization
an = 2 and 3 patients missing a baseline assessment in sildenafil 5- and 20-mg
groups, respectively
bn = 33, 32, and 33 patients contributing data in sildenafil 1-, 5-, and 20-mg
groups, respectively
cn = 33, 33, and 34 patients contributing data in sildenafil 1-, 5-, and 20-mg
groups, respectively
dn = 33, 33, and 32 patients contributing data in sildenafil 1-, 5-, and 20-mg
groups, respectively
en = 33, 32, and 32 patients contributing data in sildenafil 1-, 5-, and 20-mg
groups, respectively
fn = 33, 28, and 31 patients contributing data in sildenafil 1-, 5-, and 20-mg
groups, respectively
gn = 40 for all sildenafil groups
hn = 41, 40, and 42 patients contributing data in sildenafil 1-, 5-, and 20-mg
groups, respectively
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Neurohormones
Decreases from baseline in BNP occurred in all
groups at week 12; the response was dose related
(Fig. 6a). The sildenafil 20-mg group was statistically
significantly (P = 0.005) different from the 1-mg but
not the 5-mg group (P = 0.496). At week 24, changes
from baseline for sildenafil 20 mg were not signifi-
cantly different among groups.
Pro-BNP decreases occurred in all groups at week 12
and were dose related (Fig. 6b). Differences were signifi-
cant when sildenafil 20 mg was compared with 1 but not
5 mg (P = 0.009 and 0.414, respectively). At week 24,
changes from baseline were not significantly different
among groups.
Echocardiography
There was a trend toward a mean increase in TAPSE in
all groups, but there were no statistically significant dif-
ferences in mean TAPSE index among groups (mean
[95% CI] increases of 0.14 [0.02–0.26], 0.17 [0.06–0.28],
and 0.04 [–0.08 to 0.16] cm for sildenafil 1, 5, and
20 mg TID, respectively, at week 12 [LOCF] and 0.21
Screened (n=169)
Randomly assigned (n=130)
SIL1 mg TID (n=42)
Treated (n=41)
SIL20 mg TID (n=45)
Treated (n=43)

























Sponsor terminated study (n=1)
Adverse event (n=1)
Related to study drug (n=1)*
Discontinued (n=9)
Lost to follow-up (n=1)
Protocol violation (n=1)




Sponsor terminated study (n=5)
Other (n=1)
Discontinued (n=7)
Lost to follow-up (n=1)
Withdrew consent (n=1)




Sponsor terminated study (n=1)
Adverse event (n=1)




Sponsor terminated study (n=2)
Adverse event (n=3)
Unrelated to study drug (n=1)
Related to study drug (n=2)†
Fig. 2 Patient disposition. Legend: TID = 3 times daily; SIL = sildenafil.*Right ventricular failure. †Drug hypersensitivity (n = 1) and rash (n = 1)
Fig. 3 Plot of observed plasma sildenafil concentrations vs time after sildenafil dosing. Legend: Plasma sildenafil concentrations (open circles), sildenafil
doses of 1 mg (left), 5 mg (middle), and 20 mg (right). Median (solid line) and 90% prediction intervals (dashed lines) from simulations are overlaid. Tick
marks on the horizontal time axis indicate concentration measures below the limit of quantification. The shaded area shows the concentration range
between 3 ng/mL and 20 ng/mL, which are the average sildenafil plasma concentrations required to achieve 50% effect (EC50) and 90% effect (EC90)
on PVRI, respectively. TID = 3 times daily
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[0.06–0.37], 0.40 [0.19–0.61], and 0.15 [–0.09 to 0.39] at
week 24 [LOCF]).
Borg dyspnea score
Borg dyspnea scores trended toward reduction in all
groups (mean [95% CI] changes of –0.28 [–0.76 to 0.20],
–0.89 [–1.35 to –0.43], and –0.43 [–0.94 to 0.08] for sil-
denafil 1, 5, and 20 mg TID, respectively, at week 12
[LOCF] and –1.10 [–1.75 to –0.46], –1.07 [–1.55 to –0.58],
and –0.28 [–0.75 to 0.20] at week 24 [LOCF]), with no sig-
nificant differences between sildenafil 1- and 5-mg TID
groups compared with sildenafil 20 mg TID.
Correlations among parameters
Baseline 6MWD was weakly correlated with BNP (r=–0.19;
P= 0.0393) and pro-BNP (r=–0.22; P= 0.0145). The change
in 6MWD at week 12 was also weakly correlated with
changes at week 12 in BNP (r=–0.18; P= 0.0499) and pro-
BNP (r=–0.22; P= 0.0193).
Adverse events
The overall number of AEs and numbers of patients
reporting AEs were similar between treatment groups
in the double-blind and open-label portions of the
study; treatment-related AEs (number of AEs and
patients reporting AEs) increased with increasing dose
(Table 5). Sildenafil was generally well tolerated, with
most AEs being mild or moderate in severity. Dyspnea
was the most common AE reported in both phases of the
study; headache was the most common treatment-related
AE (Table 5). No patients discontinued as a result of ab-
normal laboratory test results, and there was no evidence
of dose-related increase in laboratory test abnormalities































Sildenafil 1 mg TID
Sildenafil 5 mg TID
Sildenafil 20 mg TID
n=41 n=40 n=42 n=34 n=36 n=36
14 m
41 m 38 m
47 m 50 m
70 m
*
*P=0.011, sildenafil 20 vs 1 mg































n=13 n=14 n=14 n=28 n=26 n=28
Baseline 6MWD











Fig. 4 Mean change from baseline in 6MWD. Legend: Mean (SE) overall change from double-blind baseline in 6MWD in double-blind (week 12) and
open-label (week 24) phases of the study (a), and change from baseline to week 12 in 6MWD by baseline 6MWD (b). All patients received sildenafil 20 mg
TID in the open-label phase of the study (weeks 13–24). 6MWD= 6-minute walk distance; TID = 3 times daily
Table 2 Change From Baselinea in 6MWD at Week 12 (LOCF)
Williams Trend Test







Least squares mean 14.21 40.75 38.36
MLE meanb 14.21 39.52 39.52
Mean differencec 24.15 −1.17 —
Williams statistic 2.37 −0.11 —
97.5% lower confidence limit 3.37 −21.48 —
P valued 0.011 0.545 —
6MWD 6-minute walk distance, LOCF last observation carried forward, MLE
maximum likelihood estimation, TID 3 times daily
aBaseline is the average of the screening and day 1 values
bMLE mean is defined as least squares mean if it satisfies descending response
relationship for descending doses; if descending relationship does not hold,
MLE mean is defined as weighted mean of adjacent least squares means
cMean difference was calculated as the least squares mean for sildenafil 20 mg
minus the MLE mean for sildenafil lower dose
dFrom directional test vs 20 mg TID
Vizza et al. BMC Pulmonary Medicine  (2017) 17:44 Page 7 of 12
Discussion
Sildenafil is one of the most widely used drugs in the
treatment of PAH. The dose of 20 mg TID was approved
based on the results of the SUPER-1 study which dem-
onstrated that Sildenafil 20 mg TID appeared to reach
the plateau of the dose-response curve for 6MWD, des-
pite the larger hemodynamic effects seen with the high-
est dosage (80 mg TID). These results raise the question
as to whether a lower dosage could have a similar effect
on 6MWD compared to the approved dose. This aspect
was addressed in the present study.
We found a significant increase from baseline in
6MWD at 12 weeks with all sildenafil doses; however,
only at higher doses (5 and 20 mg TID) was the im-
provement of a magnitude considered to be clinically
relevant (~40 m) [7, 8]. In the absence of a placebo con-
trol arm, the small non-clinically significant increase in
6MWD in the 1 mg TID group in the double blind
phase should be interpreted with caution as being a
treatment effect as it is possible that this improvement
could be seen as a “placebo effect” due to participation
in an RCT.
Among dose groups, the change in 6MWD from base-
line was significant only with sildenafil 20 mg TID com-
pared with sildenafil 1 mg TID. A Williams trend test
confirmed that sildenafil 1 mg TID was the only dose
statistically inferior to the approved dose of 20 mg TID.
Generally, patients had greater improvements in
hemodynamic parameters with sildenafil 20 mg TID ver-
sus 1 mg TID; however, these improvements were not
statistically significantly different. Significant differences
were observed between sildenafil 1 mg TID and 20 mg
TID for neurohormones at week 12.
There were no statistically significant differences between
sildenafil 20 and 5 mg TID in 6MWD, hemodynamics, or
changes in functional class.
Results from pharmacokinetic modeling showed that
the observed exposure with sildenafil 1 mg TID was
slightly below EC50 for maximal PVR change, the ob-
































90 Sildenafil 1 mg TID
Sildenafil 5 mg TID





42 m 41 m
–9 m





























































Fig. 5 Mean change from baseline in 6MWD assessed by race. Legend: Mean (SE) overall change from double-blind baseline in 6MWD in the
double-blind (week 12) phase of the study (a) and change from baseline to week 12 in 6MWD by baseline 6MWD (b) assessed by race (Asian vs
non-Asian). 6MWD = 6-minute walk distance; TID = 3 times daily
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Table 3 Adjusted Change From Baseline in Hemodynamic Parameters at Week 12
Baseline Characteristic Sildenafil Dose, TID
1 mg 5 mg 20 mg
Heart rate
n 33 32 33
LS mean (95% CI), bpm 3.4 (–1.1 to 7.9) −0.7 (–5.2 to 3.7) −5.0 (–9.3 to –0.8)
P value vs 20 mg TID 0.0019 0.1066 —
RAP
n 33 33 34
LS mean (95% CI), mmHg −0.5 (–2.3 to 1.2) −0.8 (–2.5 to 0.9) −1.7 (–3.3 to 0)
P value vs 20 mg TID 0.2741 0.4098 —
mPAP
n 33 33 34
LS mean (95% CI), mmHg −0.1 (–4.0 to 3.7) −2.2 (–5.9 to 1.5) −2.6 (–6.2 to 0.9)
P value vs 20 mg TID 0.2776 0.8458 —
Cardiac index
n 32 31 30
LS mean (95% CI), L/min/m2 0.1 (–0.2 to 0.3) 0.1 (–0.1 to 0.4) 0.1 (–0.2 to 0.3)
P value vs 20 mg TID 0.9023 0.7590 —
PVR
n 32 31 30
LS mean (95% CI), Wood units −1.2 (–3.3 to 0.9) −2.0 (–4.1 to 0) −2.4 (–4.3 to –0.4)
P value vs 20 mg TID 0.3694 0.8010 —
PVRI
n 32 31 30
LS mean (95% CI), Wood units*m2 −1.7 (–4.9 to 1.5) −3.1 (–6.2 to 0) −3.5 (–6.4 to –0.5)
P value vs 20 mg TID 0.3868 0.8628 —
MVO2
n 33 28 31
LS mean (95% CI), % 1.5 (–2.2 to 5.2) 3.0 (–0.8 to 6.7) 3.0 (–0.4 to 6.4)
P value vs 20 mg TID 0.4918 0.9791 —
bpm beats per minute, LS least squares, mPAP mean pulmonary arterial pressure, MVO2 mixed venous oxygen saturation, PVR pulmonary vascular resistance, PVRI
PVR index, RAP right atrial pressure, TID 3 times daily
Table 4 Change From Baseline to Weeks 12 and 24 in Functional Class (LOCF)
Change, n (%) Sildenafil Dose, TID
Double-Blind Phase (Week 12) Open-Label Phase (Week 24)
1 mg (n = 41) 5 mg (n = 43) 20 mg (n = 45) 1 mg (n = 41) 5 mg (n = 43) 20 mg (n = 45)
Worsened 2 classes 0 0 0 0 0 1 (2)
Worsened 1 class 1 (2) 3 (7) 2 (4) 0 3 (7) 1 (2)
No change 35 (85) 27 (63) 35 (78) 23 (56) 19 (44) 22 (49)
Improved 1 class 4 (10) 10 (23) 6 (13) 11 (27) 13 (30) 11 (24)
Improved 2 classes 1 (2) 0 0 1 (2) 1 (2) 1 (2)
Missing 0 3 (7) 2 (4) 6 (15) 7 (16) 9 (20)
LOCF last observation carried forward, TID 3 times daily
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EC50 and approaching EC90, and the observed exposure
with sildenafil 20 mg TID was mainly above EC90.
The pharmacokinetic data justify the different clinical
responses between sildenafil 1 and 20 mg TID and explain
the small difference observed between sildenafil 20 and
5 mg TID because most of the patients on 5 mg TID had
a sildenafil plasma level between 3 and 20 ng/mL.
A significant correlation among mean sildenafil plasma
concentration and 6MWD could be observed, although
the relationship between average sildenafil plasma concen-
tration and PVR appeared to show only a shallow trend.
Whether this was due to the missing placebo group or
was a consequence of the smaller sample size and larger
variability on PVR cannot be concluded but should be
interpreted on the basis of the complex interplay between
pharmacokinetics and pharmacodynamics. The vasodila-
tor effect is the result of the interplay of several factors:
tissue penetration of the drug, density and activity of
PDE5 enzyme, and severity of vascular lesions.
Smaller improvement in 6MWD at week 12 with silden-
afil 20 mg TID was observed in this study (38 m) com-
pared with SUPER-1 (45 m); however, patient populations
differed. Both studies had similar baseline 6MWD, but a
greater proportion of patients in this study had baseline
functional class II status compared with those in SUPER-1
(57% vs 39%, respectively); therefore, patients in this study
had lower-than-expected 6MWD at baseline. Patients in
our study were also younger (45 vs 49 years), with a shorter
time since diagnosis (median, 0.17 vs 0.85 years) and an in-
creased percentage of Asian patients (67% vs 7%). Geo-
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*P=0.005 and †P=0.009,
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Fig. 6 Changes from baseline in BNP (a) and pro-BNP (b) during
double-blind (week 12) and open-label (week 24) phases of the study. All
patients received sildenafil 20 mg TID in the open-label phase of the
study (weeks 13–24). BNP = B-type natriuretic peptide; TID = 3 times daily




Double-Blind Phase (Week 12) Open-Label Phasea (Week 24)
1 mg (n = 41) 5 mg (n = 43) 20 mg (n = 45) 1 mg (n = 41) 5 mg (n = 43) 20 mg (n = 45)
Patients with AEs 17 (9) 17 (10) 19 (14) 23 (11) 22 (12) 22 (15)
Patients with serious AEs 4 (0) 2 (0) 3 (1) 6 (0) 3 (0) 5 (2)
Discontinuations due to AEs 1 (1) 1 (0) 3 (2) 1 (1) 1 (0) 3 (2)
Deaths 1 (0) 1 (0) 0 0 0 0
Number of AEs 46 (12) 41 (17) 47 (24) 90 (19) 69 (27) 74 (31)
AEs occurring in ≥3 patients
Anemia 1 (0) 0 (0) 3 (1) 1 (0) 1 (0) 3 (1)
Fatigue 2 (1) 1 (0) 0 (0) 3 (1) 1 (0) 0 (0)
Nasopharyngitis 2 (0) 1 (0) 1 (0) 2 (0) 1 (0) 3 (0)
Dizziness 2 (1) 1 (0) 1 (1) 3 (1) 2 (1) 2 (2)
Dyspnea 2 (0) 3 (0) 3 (0) 2 (0) 4 (1) 3 (0)
Headache 1 (1) 1 (1) 3 (3) 2 (2) 3 (2) 3 (3)
Epistaxis 0 (0) 2 (2) 0 (0) 1 (0) 3 (3) 0 (0)
Back pain 0 (0) 1 (0) 2 (1) 1 (0) 1 (0) 3 (2)
AE adverse event, TID 3 times daily
aIncludes AEs from the double-blind and open-label portions of the study
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patients with PAH and was reported to be independent of
anthropometric factors [9]. Although few non-Asian
patients enrolled in this study, 6MWD did not appear to
differ between groups, with the exception of sildenafil
1 mg TID (Fig. 5).
Interestingly, results from the open-label phase suggest
the possibility of further improvement in 6MWD after the
first 3 months of therapy with sildenafil 20 mg TID. The
mean increase in 6MWD from baseline at the end of the
double-blind phase (41 m) was maintained in the sildenafil
5-mg group uptitrated to sildenafil 20 mg TID in the ex-
tension study (50 m), yet larger increases were observed
from the end of the double-blind study to the end of the
open-label study in the sildenafil 1- and 20-mg groups
(from 14–47 m and from 38–70 m, respectively). Thus,
sildenafil 20 mg TID maintains treatment effects regard-
less of prior low-dose treatment. However, 6MWD did not
increase to the same degree in patients previously treated
with lower doses as in patients who continuously received
20 mg TID, suggesting that a longer duration of an ad-
equate dose may confer a larger improvement in 6MWD.
Interestingly, the total improvement observed after
24 weeks in the 20-mg group (70 m) was larger than in
the SUPER-1 study at 12 weeks (48 m) or 1 year (51 m)
for all sildenafil doses combined. It may be possible that in
a population of young and mainly incident cases, as in our
study, further improvements in 6MWD may be observed
with continued sildenafil treatment.
Decreases for BNP and pro-BNP versus baseline were
significantly higher with sildenafil 20 mg versus 1 mg
TID at week 12, paralleling findings with 6MWD. BNP
levels similarly paralleled improvements (BNP levels de-
creased) or worsening (BNP levels increased) in pulmon-
ary hemodynamics and functional parameters, including
6MWD, in patients with PAH in a previous study [10].
Elevated plasma BNP levels are associated with in-
creased mortality in patients with PAH, and a decrease
in BNP levels after therapy is associated with improved
survival [11, 12]. Pro-BNP levels have recently been
shown to identify poor outcome in patients with PAH
[13, 14]. Longer-term follow-up of patients from our
study is not ongoing, which prevents any correlation
with mortality.
The main limitation of the present study is its prema-
ture termination. The study was designed to assess the
relative efficacy of sildenafil 20 mg TID and lower doses
and powered for the primary endpoint but the sample
size was not reached because of premature termination
[4, 6]. Looking at the results, this does not seem a major
issue, as the difference in the primary and secondary
endpoints between 1 mgTID and 20 mg TID is statisti-
cally significant and coherent. Regarding the comparison
between the 5-mg and 20-mg groups, the differences
were small enough that, even with the completion of the
study, similar results may have been observed. A nonin-
feriority study comparing sildenafil 5 mg TID versus
20 mg TID would require an unrealistically large sample
size for a rare disease like PAH. Estimating from the re-
sults of the current study, 382 patients would be required
for a study with a noninferiority margin of 15 m at 90%
power and a 1-sided significance level of 0.05, assuming a
true difference (5 vs 20 mg TID) of 0 m and a standard
deviation of 50 m. The required sample size would in-
crease if patient dropout was considered or if a smaller
noninferiority margin was desired.
Conclusion
Despite this study having the limitation of premature ter-
mination, sildenafil 1 mg TID, but not 5 mg TID, was
shown to be inferior to 20 mg TID for improvement in
6MWD in patients with PAH. Sildenafil 5 mg TID ap-
peared to have similar clinical and hemodynamic effects as
20 mg TID. Interestingly, 6MWD results from the open-
label phase of the study suggest that patients on the
approved sildenafil dose (20 mg TID) continued to show
clinical improvement after the first 12 weeks of treatment.
Hence, the question remains whether doses lower than
20 mg TID have therapeutic value and needs to be seen in
light of the current therapeutic approach in PAH.
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